Bristol-Myers Tops Estimates on Cancer, Hepatitis C Sales

Updated on
  • Cancer drug Opdivo brings in $305 million, beating estimates
  • Company raises full-year earnings outlook for third time

Bristol-Myers Squibb Co., a drugmaker increasingly focused on developing new cancer treatments, beat third-quarter profit estimates on better-than-expected revenue from its oncology drug Opdivo and the start of U.S. sales for its hepatitis C drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.